Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

r patients.

The first Phase l study showed that TB-403 was safe and well tolerated,

with a pharmacokinetic profile which would allow it to be developed as

a treatment for cancer. TB-403 has moved into a Phase Ib trial. This

study will look at the tolerability, pharmacokinetics and

pharmacodynamics of TB-403 in patients with advanced cancer.

- Microplasmin: Positive results announced in Phase II

clinical trials for ophthalmic indications. Positive results were

reported in ThromboGenics' Phase IIb MIVI III trial in patients with a

number of back of the eye conditions. The trial showed that the most

effective dose of microplasmin studied (125 micro g) was able to

resolve the underlying disease in approximately 30% of patients and

consequently achieved the avoidance of surgical intervention in those

patients.

Further positive six month follow-up results from the Phase IIa MIVI IIT trial, designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, were presented at the Euretina Congress in Vienna, Austria in June.

Investor Highlights

ThromboGenics has continued to work to broaden the Company's shareholder base. In July, ThromboGenics announced the acquisition of an 8% stake in the Company by a group of private investors based in Belgium in a transaction coordinated by Petercam. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics' largest shareholder. Biggar intends to remain an important shareholder in ThromboGenics for the long term.

Financial Summary

- In the first six months of 2008, revenue amounted to EUR30.3

million. This much higher level of revenue is due to Roche's upfront

payment following the signed co-development deal on TB-403. Operating

expenses were EUR13.0 million in the first half, the majority of which

were due
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , May 21, 2015  Susan ... Research (FPWR), a nonprofit organization dedicated to supporting ... Prader-Willi syndrome (PWS), announced today that FPWR has ... and Irina Shaulov contributed $1 million ... clinical initiatives.  ...
(Date:5/21/2015)... , May 21, 2015 Imagine ... feelings - and those of others. Being able to ... Analyze and read people to anticipate their thoughts and ... deepest emotions and feelings to create unique abstract paintings ... responsive games. Get inside a first-person-shooter as it creates ...
(Date:5/21/2015)... ARIZ. (PRWEB) May 21, 2015 As ... Webb Medical Center (BDWMC), Sun Health Foundation funded a ... center’s new inpatient pharmacy with the most up-to-date features ... open June 2. The pharmacy's 45 staff members will ... larger 4,895-square-foot space in the coming days. , ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Thomas Edison invented the electric light, the central power ... to extract low-grade iron ore from sand cost him millions ... 1800s. , ,Steve Jobs was fired by Apple Computers, the ... of the Segway Human Transporter and holder of 150 patents, ...
... can the cables as we move deeper into our highly ... mobility, we are nowhere without energy to power the laptops, ... has turned the average business traveler into a Socket Scout, ... and coffee houses. Indeed, Im usually the last person to ...
... Commerce (Commerce) has qualified five small businesses for investor ... Fund Tax Credit Programs. , ,"By encouraging investors through ... helping to turn these great ideas into viable, job-creating ... Investor and Venture Fund Tax Credit Programs offer Wisconsin ...
Cached Biology Technology:Embracing failure is a necessary step for successful entrepreneurs 2Embracing failure is a necessary step for successful entrepreneurs 3Power for the people 2Five technology companies qualify for investor tax credits 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... day die from breast cancer in the United States. ... taking hormone replacement therapy to avoid the effects of ... Hyder may lead to treatments for breast cancers associated ... international team, found that hormone-therapy-related breast cancer cells have ...
... extensive joint research project among two American Indian tribes ... A. Fulton Schools of Engineering at Arizona State University ... the Phoenix Metropolitan area has received a national environmental ... was awarded a 2013 National Environmental Excellence Award by ...
... new study raises concerns about possible health impacts of very ... international aid agencies are promoting to replace open-fire cooking in ... Science & Technology . Brian Just and colleagues ... on stoves or open fires that burn wood, animal dung ...
Cached Biology News:Joint air toxics research project among tribes, agencies recognized for partnership 2Joint air toxics research project among tribes, agencies recognized for partnership 3
... Dog Serum-Mixed Breed • Dog serum is collected ... one year of age Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
MOUSE ANTI BOVINE TROPONIN I...
NORMAL DONOR DONKEY SERUM...
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
Biology Products: